Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Constellation Energy Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Constellation Energy Corporation trades at $244.28 (market cap $85.60B). The key difference: Constellation Energy Corporation is far larger — about 19.1× ACADIA Pharmaceuticals Inc.'s market cap, and Constellation Energy Corporation pays a 0.71% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CEG | |
|---|---|---|
Market Cap | $4.49B | $85.60B |
Sector | Health | Energy |
52-Week High | $28.06 | $403.95 |
52-Week Low | $20.06 | $236.50 |
Enterprise Value | $3.69B | $107.27B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CEG trades at $245.87, up 2.77% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in two of the last three quarters. The company benefits from rising AI-driven electricity demand and long-term nuclear power purchase agreements with major clients like Walmart and Meta. Cash flow from operations remains robust at $4.24 billion for 2025, supporting dividend payments and growth investments.
The stock presents a compelling opportunity with a consensus price target of $343.50, implying significant upside. However, risks include high capital expenditures in 2026 leading to negative net cash flow and competitive pressures in the utilities sector. Analyst sentiment is strongly bullish with 70% buy ratings, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
